ACRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aclaris Therapeutics Inc (ACRS) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has positive analyst ratings and a promising pipeline, the technical indicators and lack of significant recent news or trading trends suggest a wait-and-see approach is more prudent.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 59.484, and moving averages are converging, signaling no clear trend. The stock is trading near its resistance level (R1: 4.611), which could act as a barrier for further upward movement.
Analysts have given consistently positive ratings with price targets ranging from $10 to $13, indicating significant upside potential. The company's ATI-052 and ATI-2138 pipeline developments have shown promising results, with several catalysts expected in the next 18-24 months.
No significant hedge fund or insider trading activity. Technical indicators do not show a strong bullish trend. The stock's recent performance suggests limited short-term upside, with a 40% chance of a slight decline in the next day and week.
No financial data available for analysis.
Analysts are optimistic, with multiple Outperform and Buy ratings. Price targets have been raised recently, reflecting confidence in the company's pipeline and growth potential.
